EWA
SPRO icon

EP Wealth Advisors’s Spero Therapeutics SPRO Stock Holding History

EP Wealth Advisors’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,500
Closed -$11.9K – 1469
2025
Q1 		$11.9K Buy
+16,500
New +$13.9K ﹤0.01% 1278

Other funds holding SPRO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCM
Monimus Capital Management Woodbridge, New Jersey $361M AUM 21.17% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

EP Wealth Advisors's SPRO Position: Q2 2025 in Review

EP Wealth Advisors sold out of Spero Therapeutics (SPRO) in Q2 2025, closing a stake of 16,500 shares — an estimated $11.9K sold.

EP Wealth Advisors first reported a position in SPRO in Q1 2025 and held it in 1 quarter. The position peaked at $11.9K in Q1 2025. 44 funds tracked by Wall St. Rank hold SPRO as of Q2 2025.

  • EP Wealth Advisors reported no remaining Spero Therapeutics position as of Q2 2025 after selling out during the quarter.
  • EP Wealth Advisors sold 16,500 Spero Therapeutics shares in Q2 2025, an estimated $11.9K.
  • EP Wealth Advisors first reported a position in Spero Therapeutics in Q1 2025 and held it in 1 quarter.
  • EP Wealth Advisors's Spero Therapeutics position peaked at $11.9K in Q1 2025.
  • 44 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2025.

Based on EP Wealth Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.